Green Park & Golf Ventures

Green Park & Golf Ventures is a Dallas-based venture capital firm with over 60 years of combined operational and financial experience. The firm focuses on early-stage investments in the healthcare and life sciences sectors, seeking opportunities that offer above-market returns for its investors. Led by Dr. Clay Heighten and Carl Soderstrom, the firm provides strategic solutions, financial backing, and a reliable network to its portfolio companies.

The firm's investment strategy is grounded in the successful methodologies that Dr. Heighten and Mr. Soderstrom used in building MedicalEdge and PhyServe. They look for companies that treat others with compassion, dignity, and respect; fresh ideas that can be disruptive to the norms in their market space; passionate, seasoned, and energetic management teams; large market opportunities with high barriers to entry; and alignment of incentives across the owners, management, and employees. Green Park & Golf Ventures enjoys superior deal flow as a result of their past experiences and vast network built on a successful operating and investment history.

Green Park & Golf Ventures has invested in several companies, including Noninvasix, which received Breakthrough Device Designation from the U.S. Food and Drug Administration for its LIVOx™ Central Venous Oxygenation Monitor, and Genomenon, which closed a $20 million Series B funding round to advance its goal of curating the entire human genome through its artificial intelligence-based Mastermind Genomic Search Engine. The firm's typical investment ranges from $500,000 to $2,000,000 and is used for either start-up or growth capital, depending on the needs of the entrepreneur and life stage of the company.